Table 4.
Diagnostic ability of Trefle® tissue acquisition and POCS-guided biopsy for differentiating extrahepatic cholangiocarcinoma from benign biliary disease.
| Sensitivity, % | Specificity, % | PPV, % | NPV, % | Accuracy, % | ||
|---|---|---|---|---|---|---|
| Trefle® | BAC | 87.5 | 100 | 100 | 85.7 | 92.9 |
| (7/8) | (6/6) | (7/7) | (6/7) | (13/14) | ||
| TB | 62.5 | 83.3 | 83.3 | 62.5 | 71.4 | |
| (5/8) | (5/6) | (5/6) | (5/8) | (10/14) | ||
| BAC + TB | 87.5 | 83.3 | 87.5 | 83.3 | 85.7 | |
| (7/8) | (5/6) | (7/8) | (5/6) | (12/14) | ||
| POCS | BAC | 40.0 | 100 | 100 | 60.0 | 68.4 |
| (4/10) | (9/9) | (4/4) | (9/15) | (13/19) | ||
| PB | 90.0 | 90.0 | 90.0 | 90.0 | 90.0 | |
| (9/10) | (9/10) | (9/10) | (9/10) | (18/20) | ||
| BAC + PB | 90.0 | 90.0 | 90.0 | 90.0 | 90.0 | |
| (9/10) | (9/10) | (9/10) | (9/10) | (18/20) |
Abbreviations: BAC, bile aspiration cytology; TB, Trefle®-assisted biopsy; PB, POCS-guided forceps biopsy; PPV, positive predictive value; NPV, negative predictive value. p value: Chi-square test.